Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2013

View Archived Issues

Inspiration and Ipsen close sale of hemophilia B product candidate

Kitasato Daiichi Sankyo files for approval of tetravalent combination vaccine in Japan

Robot-induced depression demonstrates construct validity as an experimental model

GlaxoSmithKline synthesizes new JAK3 inhibitors

KBP BioSciences patents new antibacterial agents

Beta Pharma presents new ALK/c-Met inhibitors

Pfizer divulges new tyrosine-protein kinase inhibitors

Researchers at Gerinda Therapeutics disclose novel protein kinase inhibitors

Thallion Pharmaceuticals and LFB Biotechnologies terminate collaboration

Treatment begins in AEZS-108 study in triple-negative breast cancer

Puma reaches SPA agreement for phase III trial in HER2-positive metastatic breast cancer

CEP-11981 demonstrates activity against urothelial carcinoma in mice

New Janus kinase inhibitors prepared at Almirall

NeurOp and Emory collaborate on cognitive and mental health disorders

New estrogen receptor ligands reported by Karo Bio

UCB files applications to extend approval for Cimzia in the U.S. and Europe

Array BioPharma and Genentech patent novel ERK inhibitors

Dacomitinib proves effective in bladder cancer models

Phosphagenics plans to advance oxycodone/TPM technology to clinical trials

Merck & Co. and Samsung Bioepis enter agreement

ProtAffin obtains promising preclinical data in cystic fibrosis

Intramuscular formulations of Leunase approved in Japan

Abraxane approved in Japan for additional indications

Japanese authorities approve additional formulation and indication for anti-herpes agent

Chelsea Therapeutics receives FDA guidance regarding resubmission of Northera NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...